First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day

Photocure partner Asieris today announced that “the first batch of imported Cevira^® (Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System), the world's first non-surgical, non-invasive therapy developed by Asieris Pharmaceuticals and approved for cervical intraepithelial neoplasia grade 2 (CIN2), has been officially dispatched to destinations across China following successful inspection and customs clearance at the Beijing port. 
The first batch is now being shipped to distributors and medical terminals nationwide, meaning that CIN2 patients in China – especially those of childbearing age – will soon have access to a new treatment option that requires no surgery and preserves fertility.”
Asieris also confirmed that the first prescription of Cevira had been issued in Beijing.

Read Asieris’ full media release here